CF
IONS icon

Cantor Fitzgerald’s Ionis Pharmaceuticals IONS Stock Holding History

Cantor Fitzgerald’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,880
Closed -$864K – 696
2022
Q4 		$864K Buy
+22,880
New +$962K 0.02% 414

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cantor Fitzgerald's IONS Position: Q1 2023 in Review

Cantor Fitzgerald sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 22,880 shares — an estimated $864K sold.

Cantor Fitzgerald first reported a position in IONS in Q4 2022 and held it in 1 quarter. The position peaked at $864K in Q4 2022. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

  • Cantor Fitzgerald reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 22,880 Ionis Pharmaceuticals shares in Q1 2023, an estimated $864K.
  • Cantor Fitzgerald first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Cantor Fitzgerald's Ionis Pharmaceuticals position peaked at $864K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on Cantor Fitzgerald's 13F filing for Q1 2023, filed 15 May 2023.